By Fineline Cube 
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG: 2186), has released its 2025 financial results, reporting 8.1% year-over-year revenue growth to RMB 785 million (USD 114 million) alongside multiple regulatory approvals for its biologic portfolio across diabetes, ophthalmology, and oncology indications.
Financial Performance Summary
| Metric | 2025 Result | YOY Change |
|---|---|---|
| Annual Revenue | RMB 785M (USD 114M) | +8.1% |
| Total Comprehensive Income | RMB 6.944M (USD 101M) | N/A |
| Cash Reserves | RMB 1.13B (USD 163M) | N/A |
| Reporting Period | Full Year 2025 | — |
Regulatory Approvals Timeline
Mainland China Approvals
- August 2025: Boyouping (dulaglutide) approved for blood glucose control in adult patients with type 2 diabetes mellitus
- November 2025: Boyoujing (aflibercept intravitreal injection) approved for:
- Neovascular (wet) age-related macular degeneration (nAMD)
- Diabetic macular edema (DME)
Macau Approvals
- May 2025: Three biosimilars approved for marketing:
- Boyounuo (bevacizumab biosimilar)
- Boyoubei (denosumab biosimilar)
- Boluojia (denosumab biosimilar)
Product Portfolio Analysis
| Therapeutic Area | Product | Reference Drug | Market Opportunity |
|---|---|---|---|
| Diabetes | Boyouping (dulaglutide) | Trulicity (Eli Lilly) | USD 7+ billion global GLP-1 market |
| Ophthalmology | Boyoujing (aflibercept) | Eylea (Regeneron) | USD 9+ billion anti-VEGF eye disease market |
| Oncology | Boyounuo (bevacizumab) | Avastin (Roche) | Mature but substantial biosimilar opportunity |
| Bone Health | Boyoubei/Boluojia (denosumab) | Prolia/Xgeva (Amgen) | Growing osteoporosis and oncology markets |
The diversified approval strategy spans high-growth therapeutic areas with significant commercial potential in both domestic and international markets.
Strategic Business Impact
| Factor | Implication |
|---|---|
| Revenue Diversification | Multiple product launches reduce dependency on single therapeutic area |
| Market Access | Mainland China approvals provide access to world’s second-largest pharmaceutical market |
| Biosimilar Leadership | Three simultaneous biosimilar approvals demonstrate robust development capabilities |
| Financial Strength | Strong cash position (RMB 1.13B) supports commercial launch activities and pipeline advancement |
| Parent Company Synergy | Integration with Luye Pharma Group provides commercial infrastructure and distribution network |
The 2025 approvals represent a strategic inflection point, transitioning Boan Bio from development-focused to commercial-stage operations across multiple high-value therapeutic categories.
Market Outlook & Competitive Positioning
- GLP-1 Market Entry: Boyouping positions Boan Bio in the rapidly expanding diabetes market dominated by premium-priced GLP-1 therapies
- Ophthalmology Expansion: Boyoujing addresses significant unmet need in retinal diseases with limited treatment options in China
- Biosimilar Portfolio: Dual denosumab biosimilars suggest different formulations or indications, maximizing market coverage
- Geographic Strategy: Macau approvals may serve as stepping stone to broader Greater China and international markets
- Commercial Execution: 2026-2027 expected to be critical years for market penetration and revenue realization from new products
Forward‑Looking Statements
This brief contains forward-looking statements regarding Boan Biotechnology’s financial performance, product commercialization, and market expectations. Actual commercial outcomes may vary based on pricing negotiations, market adoption, and competitive dynamics.-Fineline Info & Tech